Is androgen receptor targeting an emerging treatment strategy for triple negative breast cancer?

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Triple negative breast cancer (TNBC) is an aggressive subtype lacking estrogen/progesterone receptors and ERBB-2 amplification.
• Current TNBC treatment primarily relies on chemotherapy due to the absence of targeted endocrine or ERBB-2-directed therapies.
• TNBC exhibits significant heterogeneity, presenting challenges for effective treatment strategies.

Purpose of the Study:

• To review the role of the androgen receptor (AR) in breast carcinogenesis within the context of TNBC.
• To examine the association between AR and altered regulatory molecules and signal transduction pathways in TNBC.
• To evaluate the potential of AR-targeting strategies for specific TNBC subtypes based on preclinical and clinical data.

Main Methods:

• Literature review of preclinical and clinical studies.
• Analysis of the role of androgen receptor in breast cancer development.
• Evaluation of signaling pathways and regulatory molecules associated with AR in TNBC.

Main Results:

• The androgen receptor plays a role in breast carcinogenesis and is associated with specific molecular alterations in TNBC.
• Evidence suggests that AR signaling pathways are dysregulated in TNBC.
• Preclinical and clinical data indicate potential therapeutic relevance of targeting AR in certain TNBC subtypes.

Conclusions:

• The androgen receptor is a potential therapeutic target for specific subtypes of triple negative breast cancer.
• Targeting AR may offer novel treatment avenues for TNBC patients, complementing or replacing chemotherapy.
• Further research and clinical trials are warranted to develop and validate AR-targeting strategies for TNBC.